EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Transcriptomic Determinants of Circulating Immunity Predict Immune‐Related Adverse Events ( irAEs ) in Cancer Patients Receiving PD ‐1/ PD ‐ L1 Blockade

Liting You iD, Jianzhao Zhai iD, Zhaodan Xin, Feifei Na, Yang Wen, Jin Li, Jiajia Song, Ling Bai, Xiaohan Zhou, Binwu Ying iD, Juan Zhou

Thoracic Cancer · 2026

DOI: 10.1111/1759-7714.70265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2026. Verfasst von Liting You und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. Hauptthemen laut MEDLINE: Neoplasms, Immune Checkpoint Inhibitors, Transcriptome, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Project of Postdoctoral Foundation of Sichuan University, Young Scientists Fund of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the remarkable success of immune checkpoint inhibitor (ICI) therapy in solid tumors, immune‐related adverse events (irAEs) have posed great challenges in the whole‐course management of ICI immunotherapy. Reliable biomarkers helping to predict irAEs are still limited and lacking.

Methods

Cancer patients receiving PD‐1/PD‐L1 blockade were enrolled without limiting tumor type, immunotherapy drugs, or affected organs. Blood samples were collected for PBMC isolation. Whole transcriptomic RNA sequencing was used to discover biomarkers in PBMCs of irAEs patients, validated by RT‐PCR in the test set. IrAEs‐free survival analysis and subgroup analysis were performed. LASSO regression prediction classifiers were conducted.

Results

One hundred and two patients were enrolled, with 42 in the training set and 60 in the testing set. The transcriptomic profile of PBMCs distinguished irAEs patients of different grades from non‐irAEs patients. Five candidate biomarkers were identified: FXYD7, SPSB2, SLC35E2A, C2, and SERPING1. Lower expression of FXYD7, SPSB2, and SLC35E2A was associated with shorter irAEs‐free survival [FXYD7, HR = 3.67, p = 0.0004; SLC35E2A, HR = 3.12, p = 0.0001; SPSB2, HR = 3.41, p = 0.0110]. Higher expression of C2 and SERPING1 was associated with shorter irAEs‐free survival in severe cases [C2, HR = 0.30, p = 0.0011; SERPING1, HR = 0.39, p = 0.0082]. Classifiers based on these biomarkers predicted irAEs of all grades (AUC = 0.91) and severe irAEs (AUC = 0.94), with FXYD7, C2, and SERPING1 as key variables.

Conclusions

Together, we revealed crucial circulating immunological determinants in irAEs and provided promising biomarkers to help predict irAEs, which will enlighten future precise management and targeted treatment strategies for irAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmune Checkpoint InhibitorsTranscriptomeDrug-Related Side Effects and Adverse ReactionsBiomarkers, TumorHumansFemaleMaleMiddle AgedB7-H1 AntigenAgedProgrammed Cell Death 1 ReceptorPrognosis

Stichwörter der Autor:innen

FXYD7circulating transcriptomeimmune checkpoint inhibitorsimmune‐related adverse events

Substanzen

Immune Checkpoint InhibitorsB7-H1 AntigenBiomarkers, TumorProgrammed Cell Death 1 ReceptorCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
  • Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Sichuan, People's Republic of China.
  • Sichuan Clinical Research Center for Laboratory Medicine, Sichuan, People's Republic of China.
  • Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of…
  • Department of Thoracic Cancer, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

ORCID-Profile: Liting You, Jianzhao Zhai, Binwu Ying

Förderung

  • National Natural Science Foundation of China
  • Project of Postdoctoral Foundation of Sichuan University
  • Young Scientists Fund of the National Natural Science Foundation of China
  • Sichuan Provincial Science and Technology Support Program
  • Natural Science Foundation for Young Scientists of Shanxi Province

Zitieren

APA

You, L., Zhai, J., Xin, Z., Na, F., Wen, Y., Li, J., Song, J., Bai, L., Zhou, X., Ying, B., & Zhou, J. (2026). Transcriptomic Determinants of Circulating Immunity Predict Immune‐Related Adverse Events ( irAEs ) in Cancer Patients Receiving PD ‐1/ PD ‐ L1 Blockade. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70265

Vancouver

You L, Zhai J, Xin Z, Na F, Wen Y, Li J, et al. Transcriptomic Determinants of Circulating Immunity Predict Immune‐Related Adverse Events ( irAEs ) in Cancer Patients Receiving PD ‐1/ PD ‐ L1 Blockade. Thoracic Cancer. 2026. doi:10.1111/1759-7714.70265

BibTeX
@article{You2026,
  author = {You, Liting and Zhai, Jianzhao and Xin, Zhaodan and Na, Feifei and Wen, Yang and Li, Jin and Song, Jiajia and Bai, Ling and Zhou, Xiaohan and Ying, Binwu and Zhou, Juan},
  title = {Transcriptomic Determinants of Circulating Immunity Predict Immune‐Related Adverse Events ( irAEs ) in Cancer Patients Receiving PD ‐1/ PD ‐ L1 Blockade},
  journal = {Thoracic Cancer},
  year = {2026},
  doi = {10.1111/1759-7714.70265}
}
Kostenlos starten →